No trial has compared androgen receptor pathway inhibitors against each other in metastatic hormone-sensitive prostate cancer, so the choice between apalutamide, abiraterone and enzalutamide rests on cross-trial comparison and habit. This systematic review pooled 17 retrospective real-world studies comprising 18,626 patients, using random-effects models.
Against abiraterone, apalutamide was associated with better overall survival (hazard ratio 1.27, 95% CI 1.09 to 1.47, P = .002), better PSA90 response (odds ratio 0.70, 0.54 to 0.91), more patients reaching PSA below 0.2 ng/mL (0.49, 0.25 to 0.95) and longer time to castration resistance (1.40, 1.05 to 1.88). Apalutamide also beat enzalutamide on PSA90 (0.67, 0.5 to 0.9). Tolerability ran the other way: discontinuation for adverse events was lower with abiraterone than apalutamide (0.56, 0.37 to 0.86), with enzalutamide and apalutamide not significantly different. Abiraterone and enzalutamide looked comparable on both efficacy and safety.
Seventeen retrospective studies is not a randomised comparison, and the direction of confounding is predictable: the drug a clinician chooses depends on the patient in front of them, on cost, on cardiac and cognitive comorbidity, and on what the payer covers. In Indian practice cost usually decides this, and abiraterone with prednisolone remains by far the most affordable of the three. That is not a limitation of the evidence so much as a reminder that this analysis answers a question most clinics do not get to ask.
- Do not switch a stable patient on the strength of retrospective comparative data.
- Weigh cost first where it determines whether the patient completes treatment at all.
- Abiraterone needs prednisolone and biochemical monitoring; factor that into the comparison.
- Cardiac and cognitive comorbidity should drive the choice more than a pooled hazard ratio.
- Discontinuation for adverse events was lowest with abiraterone — a real advantage where follow-up is difficult.
The statistics, in plain English
A hazard ratio of 1.27 favouring apalutamide over abiraterone comes from studies where clinicians chose which drug each patient received, so healthier or better-insured patients may have received one preferentially — the commonest reason real-world comparisons overstate differences. Odds ratios below 1.0 for PSA response here favour apalutamide because of how the comparison was oriented; check direction before quoting such numbers. Random-effects pooling of 17 retrospective studies widens intervals appropriately but cannot remove the shared bias.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free